teclistamab,talquetamab,daratumumab,pomalidomide
genmab,janssen
['talquetamab', 'daratumumab', 'trimm-2']
canadian (&amp; international) mm expert, presents results of the trimm-2 trial (talquetamab + daratumumab), targeting gprc5d &amp; cd38, orr of 84% w/ response rate within 1st round of therapy. **impressively, 78.6% pts were refractory &amp; heavily pre-exposed to a cd38 #eha2023 
Myeloma Canada is a registered non-profit organization created by, and for, people living with myeloma. We have been Making Myeloma Matter since 2005.